Rankings
▼
Calendar
MLTX Q4 2024 Earnings — MoonLake Immunotherapeutics Revenue & Financial Results | Market Cap Arena
MLTX
MoonLake Immunotherapeutics
$1B
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$50M
Net Income
-$46M
EPS (Diluted)
$-0.72
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$48M
Free Cash Flow
-$49M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$478M
Total Liabilities
$25M
Stockholders' Equity
$447M
Cash & Equivalents
$180M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$50M
-$15M
-229.9%
Net Income
-$46M
-$7M
-513.2%
← FY 2024
All Quarters
Q1 2025 →